Immune Thrombocytopenia (ITP) - Epidemiology Forecast - 2032

DelveInsight's "Immune Thrombocytopenic Purpura (ITP) - Epidemiology Forecast-2032" report delivers an in-depth understanding of ITP historical and forecasted epidemiology of ITP in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, Spain) and the UK
• Japan

Study Period: 2019-2032.

ITP Understanding

ITP Overview

ITP, previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. The normal platelet level in adults is between 150,000/mm3 and 450,000/mm3. Platelet counts below 50,000/mm3 increase the risk of dangerous bleeding from trauma; counts below 20,000/mm3 increase the risk of spontaneous bleeding.

Classification of ITP

ITP is caused by various etiologies characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary ITP is linked to an underlying condition. When PNH is associated with AA, most patients express only a small PNH clone (<10%). Physicians could find clinical and/or biological evidence of hemolysis associated with two or three cytopenias (Hb <10 g/dL, neutrophils <1,000/μL, platelets <80,000/μL). In general, bone marrow failure dominates the clinical picture.

ITP can also be classified by disease duration. ITP has been categorized into new-onset (acute) for those diagnosed within the last 3 months, persistent for those between 3 months and 12 months, and chronic for those who have had the disease for more than 1 year. In acute ITP cases, patients usually suffer from bruising; petechia, nosebleeds, and bleeding gums may occur if the platelet count is below 20,000/mm3 compared with a normal range of 150,000-400,000/mm3. In extreme cases, patients with ITP may bleed into the lungs, brain, or other vital organs, leading to subarachnoid, intracerebral hemorrhage, or other internal bleeding are possible severe complications of this disease.

Continued in the report…

ITP Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of ITP, Age-specific Diagnosed Prevalent Cases of ITP and Gender-specific Diagnosed Prevalent Cases of ITP scenario in the 7MM covering the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.

Key Findings

• In 2021, the total cases of ITP were ~184,000 cases in the 7MM. These cases are expected to increase by 2032.
• The United States, in 2021, accounted for the highest number of cases of ITP that were ~ 65,500 cases. These cases are expected to increase by the year 2032.
• In 2021, Japan accounted for ~27,200 cases of ITP, which was approximately 15% of the total ITP cases in 7MM.
• In the UK, out of the total diagnosed prevalent cases, there were ~570 cases and ~21,400 cases ITP in children and adults, respectively in 2021. These cases are expected to increase by 2032.
• Out of the total diagnosed prevalent cases, Japan accounted for ~740 cases in children and ~21,200 cases of ITP in adults in 2021.

Scope of the Report:

• The report covers a descriptive overview of ITP, explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into ITP epidemiology and treatment.
• A detailed review of the ITP epidemiology; historical and forecasted is included in the report, covering the 7MM drug outreach.

ITP Report Insights

• Patient Population
• Therapeutic Approaches
• ITP Pipeline Analysis
• ITP Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

ITP Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• ITP Epidemiology Segmentation

Key Questions

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of ITP?
• What is the historical ITP patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient pool of ITP at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ITP?
• Out of the above-mentioned countries, which country would have the highest cases of ITP during the forecast period (2022-2032)?
• At what CAGR are these cases expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

• Develop business strategies by understanding the trends, shaping and driving the 7MM ITP epidemiology.
• The ITP epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The ITP epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.